All In Biotech

Drug Trial Radar · NCT00997035

The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo

Last checked: Nov 19, 2026Latest source record: Feb 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

240

Actual

Start

May 2010

Primary completion

Jan 2016

Study completion Mar 2016

Sponsor

Lead sponsor
University of California, San FranciscoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Aravind Eye Hospitals, India; Dartmouth-Hitchcock Medical Center; Lumbini Eye Institute and Research Centre; Bharatpur Eye Hospital; National Eye Institute (NEI)
First posted
Oct 16, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if the addition of oral voriconazole to topical treatment regimens results in lower rates of perforation in severe fungal corneal ulcers.

Conditions

  • Corneal Ulcer
  • Eye Infections, Fungal

Interventions

  • VoriconazoleDrug

    1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment. 5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment. 400 mg BID PO on study day one (loading dose), then 200 mg BID PO until 3 weeks from enrollment for patients weighing greater than 50 kg. For patients 40-50 kg, the loading dose is 300 mg BID PO on study day 1, then 150 mg BID PO until 3 weeks from enrollment. For patients weighing \<40 kg, the loading dose is 200 mg BID PO, then 100 mg BID PO until 3 weeks after enrollment.

  • PlaceboDrug

    1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment. 5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment. Two tablets BID PO on study day one, then one tablet BID PO until 3 weeks from enrollment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Perforation or Therapeutic Penetrating KeratoplastyTime frame: 3 months from enrollment

Locations

7 sites in 3 countries. Site status is shown where the registry gives one.

  • Proctor Foundation, UCSF

    San Francisco, California

  • Aravind Eye Hospital

    Coimbatore, Tamil Nadu, India

  • Aravind Eye Hospitals

    Madurai, Tamil Nadu, India

  • Aravind Eye Hospital

    Pondicherry, Tamil Nadu, India

  • Aravind Eye Hospital

    Tirunelveli, Tamil Nadu, India

  • Bharatpur Eye Hospital

    Bharatpur, Chitwan, Nepal

  • Lumbini Eye Institute

    Siddharthanagar, Lumbini, Nepal

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.